Evidence map›Paper›PMID 26248897›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.

Zhiyu Liu, Zijun Y Xu-Monette, Xin Cao, Ganiraju C Manyam, Xiaoxiao Wang, Alexandar Tzankov, Yi Xia, Xin Li, Carlo Visco, Ruifang Sun and 21 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
    Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 18 institutions in 8 countries.

Zhiyu LiuDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zijun Y Xu-MonetteDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xin CaoDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ganiraju C ManyamDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiaoxiao WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexandar TzankovUniversity Hospital, Basel, Switzerland.ORCID http://orcid.org/0000-0002-1100-3819
Yi XiaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xin LiDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carlo ViscoSan Bortolo Hospital, Vicenza, Italy.
Ruifang SunDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Santiago Montes-MorenoHospital Universitario Marques de Valdecilla, Santander, Spain.ORCID http://orcid.org/0000-0002-3565-8262
Karen DybkærAalborg University Hospital, Aalborg, Denmark.
April ChiuMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Attilio OraziWeill Medical College of Cornell University, New York, NY, USA.
Youli ZuHouston Methodist Hospital, Houston, TX, USA.
Govind BhagatColumbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.ORCID http://orcid.org/0000-0001-6250-048X
Kristy L RichardsUniversity of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-5765-6631
Eric D HsiCleveland Clinic, Cleveland, OH, USA.
William W L ChoiUniversity of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China.
J Han van KriekenRadboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Jooryung HuhAsan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
Maurilio PonzoniSan Raffaele H Scientific Institute, Milan, Italy.
Andrés J M FerreriSan Raffaele H Scientific Institute, Milan, Italy.
Ben M ParsonsGundersen Lutheran Health System, La Crosse, WI, USA.
Michael B MøllerOdense University Hospital, Odense, Denmark.
Miguel A PirisHospital Universitario Marques de Valdecilla, Santander, Spain.
Jane N WinterFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Dennis P O'MalleyClarient Pathology Services, Aliso Viejo, CA, USA.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ken H YoungDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USMarqués de Valdecilla University Hospital · ESSan Raffaele University of Rome · ITAalborg University Hospital · DKAsan Medical Center · KRCleveland Clinic · USCornell University · USGundersen Health System · USMemorial Sloan Kettering Cancer Center · USMethodist Hospital · USNewYork–Presbyterian Hospital · USNorthwestern University · USOspedale San Bortolo · ITRadboud University Nijmegen · NLUniversity of Basel · CHUniversity of Hong Kong · HKUniversity of North Carolina at Chapel Hill · USUniversity of Southern Denmark · DK

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental CoR01CA138688 · NCI · UNIVERSITY OF LOUISVILLE · PI LI, YONG · 2009 to 2017
$2.9M
Deep Sequencing of Small Regulatory RNAs in Diffuse Large B cell LymphomaRC1CA146299 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI XIAO, CHANGCHUN · 2009 to 2010
$1000k
NCI NIH HHS 1RC1CA146299NCI NIH HHS P30 CA016672NCI NIH HHS R01CA138688
6 · The paper itself

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of human neoplasms. The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear. We used standard immunohistochemistry methods to quantify survivin expression in 463 patients with de novo diffuse large B-cell lymphoma who received the R-CHOP. Of the 463 patients, 269 (58%) had survivin overexpression with a cutoff of >25%, associated with an International Prognostic Index score of >2 (P=0.015), disease in ≥2 extranodal sites (P=0.011), and a high Ki-67 index (P<0.0001). Among patients with activated B cell-like disease, the overall survival rate of survivin-positive patients was significantly lower than that of survivin-negative patients (P=0.033); multivariate analysis confirmed that in these patients, survivin overexpression was an independent prognostic factor for survival. Among patients with wild-type p53 overexpression, the overall survival and progression-free survival rates of the survivin-positive group were significantly lower than those of the survivin-negative group (P=0.035 and P=0.04 respectively). In STAT3-positive patients, survivin overexpression was associated with significantly better survival. Among patients with activated B cell-like disease, survivin-positive compared with survivin-negative groups had significantly different gene expression signatures, including genes involved in mitosis or tumor cell proliferation. Our results indicate that survivin is an independent prognostic factor for poor outcome in patients with activated B cell-like disease treated with the R-CHOP regimen, and patients with survivin-positive activated B cell-like diffuse large B-cell lymphoma seem to benefit less from this treatment and may require additional novel agents.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleHumansImmunohistochemistryInhibitor of Apoptosis ProteinsKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseAntibodies, Monoclonal, Murine-DerivedBiomarkers, TumorBIRC5 protein, humanCyclophosphamideDoxorubicinInhibitor of Apoptosis ProteinsPrednisoneR-CHOP protocolRituximabSurvivinVincristine

Identifiers

PMID26248897
OpenAlexW2137807267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.